Insights On Drug Development

  1. One-Step SAR: Using High-Content Imaging To Drive Small Molecule Protein Degraders From Hit To Lead 3/17/2026

    Discover Curia’s cost-effective high-content immunofluorescence workflow using the Revvity Opera Phenix™ system to efficiently identify small molecule protein degraders with rich, multi-dimensional data.

  2. Continuous Flow — An Emerging Alternative 3/17/2026

    Gain insights on transitioning from batch to continuous flow processes, the benefits of continuous flow chemistry, and ensuring regulatory compliance with Quality by Design (QbD) principles.

  3. Enhancing Drug Performance Through Lipid-Based Formulations For CNS Indication 3/11/2026

    Advance CNS-penetrant therapies by optimizing oral formulations to improve bioavailability, stabilize the API, and deliver more consistent and reliable drug exposure.

  4. Small Molecule Orphan Drugs: Status Quo, Challenges, And Perspectives 3/11/2026

    By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.

  5. Asymchem's World-Class TIDES Hub: Scaling Innovations For The Future 3/11/2026

    A tech‑driven, integrated ecosystem strengthens TIDES development and scale‑up, enabling reliable progression from early molecular design to commercial delivery as pipelines grow more complex.

  6. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  7. Why Your Bioanalysis Bottleneck Is Costing You More Than You Think 3/9/2026

    This piece explains why turnaround time is a strategic variable, where speed is truly achievable, and how automation reshapes the path from sample submission to decision‑ready data.

  8. Accelerator™ Drug Development 360° CDMO And CRO Solutions 3/4/2026

    Review this coordinated suite of integrated solutions that brings together CDMO and CRO capabilities across clinical research, manufacturing, and clinical supply.

  9. Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development 3/3/2026

    Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.

  10. Navigating Nitrosamine Impurities In Pharmaceutical Drug Development 3/3/2026

    Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.